Last $1.73 USD
Change Today +0.02 / 1.17%
Volume 107.7K
APPY On Other Exchanges
Symbol
Exchange
APPY is not on other exchanges.
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

venaxis inc (APPY) Snapshot

Open
$1.71
Previous Close
$1.71
Day High
$1.75
Day Low
$1.70
52 Week High
03/13/14 - $3.88
52 Week Low
09/3/13 - $1.43
Market Cap
53.6M
Average Volume 10 Days
172.2K
EPS TTM
$-0.50
Shares Outstanding
31.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENAXIS INC (APPY)

Related News

No related news articles were found.

venaxis inc (APPY) Related Businessweek News

No Related Businessweek News Found

venaxis inc (APPY) Details

Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The company’s research and development activities primarily focus on a human acute appendicitis blood-based test. Its lead product candidate includes APPY1, a novel blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. Venaxis, Inc., through its license agreement with Washington University in St. Louis, develops, markets, sells, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for bovine, equine, and swine animals. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

venaxis inc (APPY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $325.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $231.8K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $236.9K
Compensation as of Fiscal Year 2013.

venaxis inc (APPY) Key Developments

Venaxis, Inc. - Special Call

To discuss on the progress of the APPY1 FDA submission

Venaxis Reports on Recent FDA Submission Activities

Venaxis, Inc. updated on recent activities concerning its U. S. Food and Drug Administration (FDA) submission for the APPY1 Test that was filed in March 2014. The FDA has reviewed the submission, and provided Venaxis with questions and information requests on the submission. Venaxis is compiling responses to the FDA's questions and their requests for additional data and information, as well as seeking clarification from the FDA on certain of its requests.

Venaxis, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 01:00 PM

Venaxis, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 01:00 PM. Venue: InterContinental Hotel, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Stephen T. Lundy, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APPY:US $1.73 USD +0.02

APPY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APPY.
View Industry Companies
 

Industry Analysis

APPY

Industry Average

Valuation APPY Industry Range
No financial data is available for APPY.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENAXIS INC, please visit www.venaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.